“Radical Prostatectomy in the Management of Clinically Localized Prostate Cancer”
Raboy A., Albert P., and Ferzli G.
In this study 10 patients received
retropubic prostatectomy as monotherapy
for their prostate
cancer removal. This treatment was performed with
a small suprapubic midline 5-cm incision compared to
the usual 8-10cm incisions. To assist the visualization
of physicians a laparoscopic port was used. Doctors
implemented conventional-operating instruments and standard
radical prostatectomy steps were taken. Patients had
an average body mass index of 24.1. The average operating
time took 259 minutes with an average blood loss reaching
1, 594mL. Out of 10, 2 patients required conversion
to open surgery. One year after surgery 88% of prostatectomy
patients were fully continent and 75% maintained potency.
“Cancer Progression and Survival Rates Following Anatomical Radical Retropubic Prostatectomy in 3,478 Consecutive Patients: Long-Term Results”
Roehl, K.A., Han M., Ramos C.G., Antenor J.A.V., and Catalona W.J.
This study evaluated long-term prostate cancer survival rates in 3,478 patients who have undergone radical retropubic prostatectomy. Doctor William J. Catalona was the lead physician who performed this procedure in all cases. Patients were approximately 61 years old. After surgery patients were tracked with semiannual prostate specific antigen tests and annual digital rectal exams. Due to adverse findings in the radical prostatectomy specimen, 217 men (6%) chose to receive adjuvant radiotherapy. Fifty-nine men (2%) were lost to follow-up. For all other patients doctors generally followed-up after 65 months. With the use of a Kaplan-Meier product certain 10-year predictions could be established. At 10-years 68% of patients were biochemical progression-free, 97% were cancer specific free and 83% experienced overall survival.
“Neoadjuvant Hormone Therapy Before Salvage Radiotherapy for an Increasing Post-radical Prostatectomy Serum Prostate Specific Antigen Level”
TIGUERT, RABI; RIGAUD, JEROME; LACOMBE, LOUIS; LAVERDIERE, JACQUES; FRADET, YVES Journal of Urology. 170(2, Part 1):447-450, August 2003.
Within this study doctors retrospectively evaluated 81 patients who were treated with neoadjuvant androgen deprivation therapy before salvage external beam radiation treatment due to an increased PSA level following radical retropubic prostatectomy. Patients were analyzed based on the outcome of preoperative, pathological, postoperative characteristics, pre-salvage treatment, and radiation therapy. Prior to the salvage radiotherapy patients received a 3-month injection of a luteinizing hormone-releasing hormone analogue. Doctors followed up with their patients approximately 38 months after external beam radiation and 91 months after radical prostatectomy. At 3 years 75% of patients were free of biochemical failure and 50% were at 5 years. Two patients (2%) died of prostate cancer. Those who benefited most from this treatment were patients with a pre-radiation PSA level less than 1 and a Gleason score less than 7.